Cargando…

Pneumonitis and pulmonary fibrosis in a patient receiving adjuvant docetaxel and cyclophosphamide for stage 3 breast cancer: a case report and literature review

INTRODUCTION: Pulmonary toxicities associated with chemotherapeutic agents utilized as adjuvant therapy in patients with breast cancer are distinctly uncommon. The chemotherapy regimen of docetaxel/cyclophosphamide has a more favorable therapeutic index compared to anthracycline-based regimens due t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ochoa, Roberto, Bejarano, Pablo A, Glück, Stefan, Montero, Alberto J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3533898/ https://www.ncbi.nlm.nih.gov/pubmed/23198815 http://dx.doi.org/10.1186/1752-1947-6-413

Ejemplares similares

Clinical Impact of Primary Prophylactic Pegfilgrastim in Breast Cancer Patients Receiving Adjuvant Docetaxel-Doxorubicin-Cyclophosphamide Chemotherapy
por: Jeon, Ye Won, et al.
Publicado: (2020)

Comparative study of adjuvant chemotherapeutic efficacy of docetaxel plus cyclophosphamide and doxorubicin plus cyclophosphamide in female breast cancer
por: Adeel, Muhammad, et al.
Publicado: (2019)

Docetaxel-related interstitial pneumonitis
por: Wang, Chung-Jen, et al.
Publicado: (2015)

Dose-Dense Epirubicin and Cyclophosphamide Followed by Docetaxel as Adjuvant Chemotherapy in Node-Positive Breast Cancer
por: Mirzaei, Hamid Reza, et al.
Publicado: (2013)

It Is Not Pneumocystis jiroveci (PCP), It Is Cyclophosphamide-Induced Pneumonitis
por: Bartl, Mery, et al.
Publicado: (2023)

Comparison of the effectiveness and toxicity of neoadjuvant chemotherapy regimens, capecitabine/epirubicin/cyclophosphamide vs 5-fluorouracil/epirubicin/cyclophosphamide, followed by adjuvant, capecitabine/docetaxel vs docetaxel, in patients with operable breast cancer
por: Zhang, Minmin, et al.
Publicado: (2016)

Life-threatening hypersensitivity pneumonitis induced by docetaxel (taxotere)
por: Wang, G-S, et al.
Publicado: (2001)

Four cycles of docetaxel and cyclophosphamide as adjuvant chemotherapy in node negative breast cancer: A real-world study
por: Batra, Atul, et al.
Publicado: (2020)

Cyclophosphamide/docetaxel/pegfilgrastim: Various toxicities: case report
Publicado: (2021)

Correlation of UGT2B7 Polymorphism with Cardiotoxicity in Breast Cancer Patients Undergoing Epirubicin/Cyclophosphamide-Docetaxel Adjuvant Chemotherapy
por: Li, Hai, et al.
Publicado: (2019)

Cost-effectiveness of paclitaxel, doxorubicin, cyclophosphamide and trastuzumab versus docetaxel, cisplatin and trastuzumab in new adjuvant therapy of breast cancer in china
por: Xu, Qiaoping, et al.
Publicado: (2021)

Incidence of Febrile Neutropenia in Korean Female Breast Cancer Patients Receiving Preoperative or Postoperative Doxorubicin/Cyclophosphamide Followed by Docetaxel Chemotherapy
por: Kim, Chang Gon, et al.
Publicado: (2016)

Pharmacokinetics and safety of cyclophosphamide and docetaxel in a hemodialysis patient with early stage breast cancer: a case report
por: Yang, Liu, et al.
Publicado: (2015)

Clinical utilization of long-acting granulocyte colony-stimulating factor (pegfilgrastim) prophylaxis in breast cancer patients with adjuvant docetaxel-cyclophosphamide chemotherapy
por: Jeon, Ye Won, et al.
Publicado: (2021)

Acute exacerbation of idiopathic pulmonary fibrosis: usual interstitial pneumonitis vs. possible usual interstitial pneumonitis pattern
por: Cao, Meng-Shu, et al.
Publicado: (2019)

Differential immunomodulatory effects of epirubicin/cyclophosphamide and docetaxel in breast cancer patients
por: Wimmer, Kerstin, et al.
Publicado: (2023)

Idiopathic Pulmonary Fibrosis Update: Reconciliation with Hypersensitivity Pneumonitis Guidelines Required?
por: Moran-Mendoza, Onofre
Publicado: (2022)

Advanced Stage Is a Risk for Severe Neutropenia in Breast Cancer Patients Undergoing Neoadjuvant Adriamycin/Cyclophosphamide/Docetaxel Chemotherapy
por: Moro, Kazuki, et al.
Publicado: (2022)

Phase II study of adjuvant docetaxel and carboplatin with/without doxorubicin and cyclophosphamide in triple negative breast cancer: a randomised controlled clinical trial
por: Najafi, Safa, et al.
Publicado: (2017)

Lipidomics of cyclophosphamide 4‐hydroxylation in patients receiving post‐transplant cyclophosphamide
por: Navarro, Sandi L., et al.
Publicado: (2022)

Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy
por: Lee, Kyung-Hun, et al.
Publicado: (2007)

Dose response of pegfilgrastim in Japanese breast cancer patients receiving six cycles of docetaxel, doxorubicin, and cyclophosphamide therapy: a randomized controlled trial
por: Masuda, Norikazu, et al.
Publicado: (2015)

Relevance of RNA N6-Methyladenosine Regulators for Pulmonary Fibrosis: Implications for Chronic Hypersensitivity Pneumonitis and Idiopathic Pulmonary Fibrosis
por: Zhou, Yiyi, et al.
Publicado: (2022)

Docetaxel-Induced Fatal Interstitial Pneumonitis in a Patient with Castration-Resistant Prostate Cancer
por: Min, Byung-Dal, et al.
Publicado: (2012)

Adjuvant Capecitabine With Docetaxel and Cyclophosphamide Plus Epirubicin for Triple-Negative Breast Cancer (CBCSG010): An Open-Label, Randomized, Multicenter, Phase III Trial
por: Li, Junjie, et al.
Publicado: (2020)

Immunoglobulin Free Light Chains Are Increased in Hypersensitivity Pneumonitis and Idiopathic Pulmonary Fibrosis
por: Groot Kormelink, Tom, et al.
Publicado: (2011)

Multiplex protein profiling of bronchoalveolar lavage in idiopathic pulmonary fibrosis and hypersensitivity pneumonitis
por: Stijn, Willems, et al.
Publicado: (2013)

The Respiratory Microbiome in Chronic Hypersensitivity Pneumonitis Is Distinct from That of Idiopathic Pulmonary Fibrosis
por: Invernizzi, Rachele, et al.
Publicado: (2021)

Corrigendum: Relevance of RNA N6-methyladenosine regulators for pulmonary fibrosis: Implications for chronic hypersensitivity pneumonitis and idiopathic pulmonary fibrosis
por: Zhou, Yiyi, et al.
Publicado: (2022)

Adjuvant Docetaxel and Cyclophosphamide (DC) with Prophylactic Granulocyte Colony-Stimulating Factor (G-CSF) on Days 8 &12 in Breast Cancer Patients: A Retrospective Analysis
por: Yerushalmi, Rinat, et al.
Publicado: (2014)

Cut from the Same Cloth: Similarities between Hypersensitivity Pneumonitis and Idiopathic Pulmonary Fibrosis
por: Yang, Monica M., et al.
Publicado: (2021)

Emphysematous Cystitis in a Patient Receiving Cyclophosphamide
por: Al Zein, Said
Publicado: (2021)

Phase III placebo-controlled, double-blind, randomized trial of pegfilgrastim to reduce the risk of febrile neutropenia in breast cancer patients receiving docetaxel/cyclophosphamide chemotherapy
por: Kosaka, Yoshimasa, et al.
Publicado: (2015)

Pilot study of bevacizumab in combination with docetaxel and cyclophosphamide as adjuvant treatment for patients with early stage HER-2 negative breast cancer, including analysis of candidate circulating markers of cardiac toxicity: ICORG 08–10 trial
por: Gullo, Giuseppe, et al.
Publicado: (2019)

Phase I study of docetaxel in combination with cyclophosphamide as first-line chemotherapy for metastatic breast cancer
por: Vasey, P A, et al.
Publicado: (2002)

Grade 4 Pneumonitis in a Patient Treated with a Combination of Gemcitabine and Docetaxel for Recurrent Leiomyosarcoma of the Uterus
por: Wang, Connor, et al.
Publicado: (2020)

Pharmacokinetic evaluation of two pirfenidone formulations in patients with idiopathic pulmonary fibrosis and chronic hypersensitivity pneumonitis
por: Barranco-Garduño, Lina Marcela, et al.
Publicado: (2020)

Reply to Moran-Mendoza: Idiopathic Pulmonary Fibrosis Update. Reconciliation with Hypersensitivity Pneumonitis Guidelines Required?
por: Raghu, Ganesh, et al.
Publicado: (2022)

Changes in ovarian function in premenopausal women with breast cancer undergoing adjuvant TC (docetaxel and cyclophosphamide) chemotherapy during a brief period of amenorrhea around the last chemotherapy cycle
por: Yoshimura, Keiko, et al.
Publicado: (2014)

Dose-Dense Docetaxel versus Weekly Paclitaxel following Dose-Dense Epirubicin and Cyclophosphamide as Adjuvant Chemotherapy in Node-Positive Breast Cancer Patients: A Retrospective Cohort Analysis
por: Khoshroo, Sara, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_4ji8i1gisusv21lcn6oc8gi4h0